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Abstract
Background: In an effort to overcome the barriers to BCT, alternative methods of delivering
radiation therapy have been explored. APBI allows the radiation treatment to be accomplished in
one week or less. XB is a form of balloon-based APBI that uses an electronic source generated by
a mobile controller unit. Investigators have also explored IORT treatment that delivers a single
fraction of radiation in the operating suite at the time of surgery.
Methods: We report on the first patient treated with XB to deliver IORT.
Results: IORT treatment utilizing XB is feasible and can be accomplished with a total procedure
time of approximately 2 hours.
Conclusion: Further research on XB and other methods of IORT is needed to establish clinical
efficacy and safety for patients with early-stage breast cancer.
Background
Several large randomized trials with extended follow-up
have shown that breast conserving therapy (BCT) offers
equivalent overall survival to modified radical mastec-
tomy in patients with early stage breast cancer [1,2]. Stud-
ies have also shown that in certain parts of the United
States, as few as 10% of eligible patients receive BCT [3,4].
Instead, some women are treated with mastectomy and
others receive lumpectomy alone. This is especially com-
mon for women who live at an increased distance from
radiation centers [5,6]. The logistical difficulties that
accompany a 6–7 week course of whole breast external
beam radiation (EBRT) are believed to be the main deter-
rent to patients receiving radiation therapy. Although
radiation therapy is burdensome, it is an important com-
ponent of BCT that cannot be safely omitted. EBRT has
been shown to both decrease the risk of local recurrence
and also to improve overall survival compared to surgery
alone [7].
In an effort to overcome the barriers to BCT, alternative
methods of delivering radiation therapy have been
explored. In contrast to standard EBRT, which treats the
whole breast, accelerated partial breast irradiation (APBI)
delivers radiation to the lumpectomy bed plus a 1–2 cm
margin only. By decreasing the volume of treatment and
increasing the daily fraction size of the radiation, treat-
ment can be accomplished in one week rather than the
standard 6–7 weeks.
The method of APBI with the longest published experi-
ence is multi-catheter interstitial brachytherapy. In this
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technique, several rows of catheter needles are placed
around the lumpectomy bed and loaded with radiation
sources. Multi-catheter interstitial brachytherapy has been
associated with local recurrence rates of less than 5% at
over 5-years follow-up and favorable cosmesis [8,9].
Unfortunately, this technique is difficult and requires sig-
nificant expertise. As a result, multi-catheter interstitial
breast brachytherapy is performed at relatively few centers
in the U.S.
Balloon-based APBI methods were developed to simplify
the brachytherapy procedure. The MammoSite™ (MS)
brachytherapy applicator was the first balloon catheter to
be developed for APBI. The catheter contains an inflation
channel and a channel for the passage of an Iridium-192
(Ir-192) radiation source. It can be inserted through a sin-
gle incision at the time of surgery or post-lumpectomy
using ultrasound guidance. Initial results regarding cos-
mesis and local control using the MS catheter have been
comparable to multi-catheter interstitial brachytherapy
[10,11].
Additional methods of balloon-based APBI are also being
explored. A modified form of balloon-based brachyther-
apy called Xoft Axxent Electronic Brachytherapy™ (XB)
received FDA clearance for the treatment of breast cancer
in January, 2006. This device uses a mobile controller,
which generates kilovoltage (kV) x-rays. This approach to
APBI requires minimal shielding and thus has the poten-
tial to increase the number of settings in which radiation
treatments can be offered. In addition, XB is not limited
by rigorous radiation source regulations associated with
other methods of APBI, which utilize radioisotope
sources. The early results of a clinical trial to evaluate the
performance and safety of XB in the outpatient treatment
of early-stage breast cancer patients were recently pre-
sented at the American Society of Clinical Oncology
(ASCO) Breast Cancer Symposium. Treatment with XB
was found to be feasible and associated with minimal
acute side effects [12].
Investigators have also explored delivering APBI in the
operating room immediately after lumpectomy. Intraop-
erative radiation therapy (IORT) allows the patient to
receive all her radiation in a single fraction before she
awakens from surgery. Additional potential advantages
include delivering the radiation before tumor cells have a
chance to proliferate, performing the radiation under
direct visualization at the time of surgery, and decreasing
healthcare costs. Published results using IORT both as a
tumor bed boost in conjunction with EBRT and as a pri-
mary treatment in APBI have shown favorable outcomes
[13-15].
To date, XB has been utilized only in an outpatient setting
to deliver APBI in 10 fractions over 5 days. We report on
the first patient treated using XB to deliver IORT as part of
an IRB approved single-institution trial.
Patients and methods
The patient is a 61-year-old woman who presented with
an abnormal screening mammogram. It revealed an 8-
mm mass in the lower inner quadrant of the left breast.
She had a core biopsy performed that showed a Grade 1,
infiltrating ductal cancer that was estrogen and progester-
one receptor positive.
The patient was seen in consultation by her surgeon and
radiation oncologist. Radiation treatment options were
explained to the patient, including the standard of care, 6–
7 weeks of whole breast radiation therapy, and one week
of outpatient APBI. An IRB approved protocol utilizing XB
to deliver IORT was also discussed. The patient opted to
enroll in the IORT protocol.
On September 3rd, 2008, the patient underwent a lumpec-
tomy and sentinel lymph node biopsy. The tumor mass
and margins of excision were sent for permanent section,
and the identified sentinel lymph node was sent for fro-
zen section. The pathology department reviewed the
lymph node specimen at the time of surgery and informed
the treating physicians that it was uninvolved by cancer.
At that point, additional breast tissue was removed poste-
rior to the lumpectomy cavity down to the depth of the
superficial pectoralis fascia to accommodate the chest wall
shield. A pliable piece of lead was then temporarily placed
over the chest wall to shield the ribs, lung, and heart, from
scatter radiation. A cavity evaluation device (CED) was
then inserted into the lumpectomy cavity through a small
incision in the lateral breast and inflated with exactly 40
cc of saline (Figure 1). The conformity of the CED to the
surrounding breast tissue was then evaluated under direct
visualization. Conformance was considered to be accept-
able if less than 10% of the tissue immediately surround-
ing the breast tissue was composed of fluid or air and the
balloon was tightly opposed to the lumpectomy cavity.
Conformance was found to be inadequate, so an addi-
tional 10 cc of saline was inserted into the balloon. It was
found that conformance was still less than ideal, so an
additional 10 cc, or at total of 60 cc, was inserted into the
balloon.
Since a CED inflated to 60 cc was found to be the proper
size, a 4 × 5 cm XB balloon catheter kit was then opened
by the OR staff. The CED was then deflated and removed
and a XB was then inserted in place of the CED. If a 40 cc
balloon were to be used, a 3 × 4 cm catheter kit would
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the XB controller. Radiation plans for a 40 cc, 50 cc, 60 cc,
and 70 cc balloon were previously developed by CT scan-
ning the XB catheter inflated with saline to the 4 sizes in a
water phantom. These plans were then loaded onto USB
drives. At the completion of calibration, which typically
takes approximately 15 minutes, the physicist then loaded
the corresponding radiation plan onto the controller unit.
During machine calibration, retention sutures were
placed in the breast tissue superficial to the inflated bal-
loon (Figure 2). The retention sutures serve to build-up
the subcutaneous tissue to potentially increase the bal-
loon-to-skin distance and to more closely approximate
the balloon to the surrounding breast tissue. An intraop-
erative ultrasound was then performed to evaluate the bal-
loon-to-skin distance and the degree of air and/or fluid in
the breast tissue surrounding the balloon. For the pur-
poses of this protocol, a minimum of 1-cm balloon to
skin distance is required. If the patients are found to have
≥ 0.7-cm and < 1.0-cm of balloon-skin-distance they are
offered outpatient balloon-based ABPI. If patients have a
balloon-skin-distance of < 0.7-cm, balloon-based brachy-
therapy is aborted. If patients are found to have large air
pockets surrounding the balloon on ultrasound, the bal-
loon is inflated by 10 cc to the next largest size and re-eval-
uated via ultrasound.
The patient was found to have 1.6-cm balloon-to-skin dis-
tance and no air pockets surrounding the balloon, so the
decision was made to proceed with IORT (Figure 3). A sec-
ond sterile drape was then placed over the operative field,
so that the radiation therapy could be delivered without
contaminating the field. The catheter end was passed
through a hole in the drape and a FlexiShield™ (FS) was
placed on top of the drape (Figure 4). The FS is a lead-
equivalent material, which serves to decrease transmis-
sion to the patient and hospital staff.
Results
The radiation oncologist then broke scrub, attached the
XB controller to the catheter, and inserted the radiation
source into the balloon. The radiation therapy was then
A CED is inserted through a small incision in the lateral  breast and inflated with exactly 40 cc, 50cc, 60 cc, or 70 cc Figure 1
A CED is inserted through a small incision in the lat-
eral breast and inflated with exactly 40 cc, 50 cc, 60 
cc, or 70 cc.
Retention sutures are placed to potentially increase the bal- loon-to-skin distance and to more closely approximate the  balloon to the surrounding breast tissue Figure 2
Retention sutures are placed to potentially increase 
the balloon-to-skin distance and to more closely 
approximate the balloon to the surrounding breast 
tissue.
Ultrasound image showing a balloon-skin-distance of 1.6-cm  and no evidence of air pockets surrounding the balloon Figure 3
Ultrasound image showing a balloon-skin-distance of 
1.6-cm and no evidence of air pockets surrounding 
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initiated. A total of 20 Gy to the balloon surface was deliv-
ered in approximately 20 minutes (Figure 5). The anesthe-
siologist, surgeon, and radiation oncologist remained in
the room during the radiation delivery either wearing lead
aprons or standing behind a mobile radiation shield. At
the completion of the radiation, the balloon and tempo-
rary chest wall shield were removed and the incisions were
closed. The duration of the entire procedure including
lumpectomy, sentinel lymph node biopsy, balloon cathe-
ter placement, radiation therapy, and closing the incisions
was approximately 2 hours.
Margin status was assessed by permanent section after the
completion of the surgery. Negative microscopic margins
are required in the protocol for treatment with IORT
alone. Patients who are found to have microscopically
positive margins of excision are offered re-excision and
whole breast EBRT. The patient was found to have mar-
gins of excision of over 2-mm
Discussion
XB is a novel form of balloon-based APBI, which uses an
electronic source to generate kV x-rays. This form of APBI
eliminates the need for an HDR afterloader device, heavy
shielding, and regulations associated with radiosotope
handling and disposal. In addition, XB increases the
number of settings in which radiation can be performed.
Early clinical reports have shown this technique to be fea-
sible and associated with minimal acute toxicity [12].
Also, XB has been compared to MS (a more established
form of balloon-based APBI) and found to offer equiva-
lent target volume coverage with increased normal tissue
sparing [16]. To date and since FDA clearance, XB has only
been used for outpatient treatment of breast and endome-
trial cancer. The mobile nature of the XB controller, as
well as, the limited shielding requirements make XB a log-
ical modality to be utilized for IORT in the treatment of
early-stage breast cancer.
Delivering IORT treatment in a single session is not a new
concept. Older IORT techniques involved cumbersome
machinery or required custom-built heavily shielded
operating suites. Other institutions have performed IORT
by transferring patients from the operating room to the
radiation oncology department during surgery.
Newer devices for the delivery of IORT utilize smaller,
more mobile technology. Two modern mobile linear
accelerators have been developed which use 4–6 MeV
electrons to deliver a physical dose of approximately 21
Gy [15,17]. An additional device used to deliver IORT is
the Intrabeam™ (IB) device, which like XB, uses a 50 kV x-
ray source. The IB device delivers 20 Gy at the surface of a
solid spherical applicator and approximately 5 Gy at 1-cm
depth [18,19]. This is in contrast to XB IORT, which deliv-
ers 20 Gy at the surface of the balloon applicator and 9–
10 Gy at 1-cm depth. It is unknown whether the increased
dose at 1-cm depth associated with XB will have a clinical
benefit or possibly increase the risk of toxicity. XB and IB
methods of IORT are compared in Table 1.
Long-term data regarding the safety and efficacy of IORT
are not available. The TARGIT trial is a phase III prospec-
tive, randomized trial comparing single fraction IORT
delivered with IB to conventional whole breast EBRT. Six-
teen international institutions are enrolling patients in the
trial. Eligible patients include patients ≥ 35 years of age
A sterile drape is placed over the operative field and a Flex- iShield™ is placed on top of the drape to minimize radiation  transmission Figure 4
A sterile drape is placed over the operative field and 
a FlexiShield™ is placed on top of the drape to mini-
mize radiation transmission.
A radiation dose of 20 Gray to the balloon surface is deliv- ered in approximately 20 minutes Figure 5
A radiation dose of 20 Gray to the balloon surface is 
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with T1-T3, N0 tumors eligible for BCT. Patients with
multi-focal or multi-centric lesions, clinically positive
lymph nodes, extensive intraductal component, or inva-
sive lobular cancers are not eligible for enrollment [19].
The results of the TARGIT trial will help determine
whether IORT is an equivalent alternative to standard
whole breast EBRT. If IORT methods, including XB, are
established as a standard treatment option, this may allow
increased access to BCT, as well as, improved quality of
life and decreased medical costs for patients with a diag-
nosis of early-stage breast cancer.
Conclusion
IORT utilizing XB is feasible and can be accomplished in
a total procedure time of approximately 2 hours. To date,
there are no long-term results utilizing this technique, and
patients continue to be enrolled as part of an IRB
approved single institution trial. Further research on XB
and other methods of IORT is needed to establish clinical
efficacy and safety for patients with early-stage breast can-
cer.
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